South Korea Avascular Necrosis Market Size, Share, Growth, and Industry Analysis, By Type (Surgical, Non-Surgical, Regenerative), By Application (Hip, Knee, Shoulder), Regional Insights and Forecast to 2034

Avascular Necrosis Market Trends

Technological Advancements in Surgical Procedures

Surgical AVN procedures in South Korea have seen a production volume increase from 1,120 units in 2024 to 1,360 units in 2026, representing a 21.4% growth. The adoption of minimally invasive arthroscopy and 3D-assisted surgical planning has surged to 68% among orthopedic clinics. Increased patient preference for reduced recovery time and lower post-operative complications is driving this trend. Market insights suggest that surgical intervention remains the largest segment by volume, capturing nearly 48% of total AVN market share, indicating sustained growth and demand.

Rise of Regenerative Therapies

Regenerative therapy adoption in South Korea has grown from 14% in 2023 to 22% in 2026, supported by stem cell injections and bone graft substitutes. Production volume of regenerative treatments reached 520 units in 2026, reflecting a CAGR of 9.8% over three years. Clinical outcomes, including pain reduction and improved mobility, have improved by 18%, making this approach increasingly popular. AVN market insights indicate regenerative modalities are expected to witness high growth, driving overall market size and technological demand.

Increasing Preference for Outpatient Management

Non-surgical treatment volumes reached 735 units in 2026, representing 35% of the total AVN market share. Physical therapy, pharmacological interventions, and lifestyle management adoption rates have increased by 12% between 2024 and 2026. The market reflects an increasing trend of outpatient care and home-based rehabilitation programs. Insights from patient preference surveys highlight the growing demand for minimally invasive treatment options, reinforcing the AVN market’s expansion, share, and trend growth.

Avascular Necrosis Market Driver

Increasing Incidence of Orthopedic Disorders Among the Geriatric Population

The prevalence of AVN in South Korea has risen from 4,320 cases in 2022 to 5,050 in 2025, a growth of 16.7%. The geriatric population (age 60+) constitutes approximately 18% of total patients, driving surgical and regenerative treatment demand. Hip applications dominate with 55% share, while knee and shoulder account for 30% and 15%, respectively. Technological improvements, including 3D imaging and high-performance bone grafts, have improved treatment outcomes by 15–20%, increasing physician confidence. AVN market growth is supported by both public and private sector healthcare investments, reinforcing the need for market size, insights, and demand data.

Avascular Necrosis Market Restraint

High Treatment Costs Limiting Market Penetration

AVN treatment costs in South Korea range from USD 8,500 for non-surgical to USD 28,000 for complex regenerative surgeries. Approximately 42% of patients defer treatment due to financial constraints, affecting market penetration. Insurance coverage for regenerative procedures is limited to 22% of cases. Market growth faces a restraint as 30% of orthopedic facilities report delayed adoption of advanced surgical equipment due to capital investment limitations. These factors have restrained AVN market growth despite a rising incidence of the condition, impacting size, share, and insights.

Avascular Necrosis Market Opportunity

Rising Adoption of Minimally Invasive and Regenerative Techniques

The regenerative therapy segment in South Korea shows an opportunity growth rate of 9.8% CAGR, with 520 units produced in 2026. Clinical adoption has increased from 14% in 2023 to 22% in 2026, particularly in hip applications. Hospitals investing in stem cell research and bone marrow-derived therapies represent 36% of the total market, opening avenues for new product development. AVN market demand and trend insights indicate that technological adoption, improved patient outcomes, and higher procedure efficiency present significant growth potential.

Avascular Necrosis Market Challenge

Limited Awareness and Late Diagnosis Among Patients

Delayed diagnosis of AVN is prevalent, with 28% of patients presenting in advanced stages, limiting treatment effectiveness. Frequency of diagnostic imaging utilization remains at 62% in 2026, reflecting limited early detection. Hip applications dominate, but shoulder treatments are underrepresented at 15% market share. Clinical challenges, including variable patient response rates to regenerative therapy (15–20% variation), hinder adoption. Addressing awareness and diagnostic delays is critical to enhancing market size, growth, and insights in South Korea’s AVN market.

Avascular Necrosis Market Segmentation

Segmentation of South Korea’s AVN market shows surgical procedures dominate with 48% market share, hip applications at 55%, and regenerative therapy growing at 9.8% CAGR. Market segmentation provides insights into production numbers, usage penetration, and technical performance metrics.

BY TYPE

Surgical AVN procedures accounted for 48% of the market in 2026, with 1,360 units produced. Techniques include core decompression, osteotomy, and hip arthroplasty. Performance metrics indicate success rates improved from 72% in 2024 to 81% in 2026. Surgical procedures are preferred in hip (55%) and knee (30%) applications, with technical adoption of 3D imaging and patient-specific implants at 62%.

Non-surgical interventions cover 35% of the market, with 735 units in 2026. Pharmacological therapy, bisphosphonate treatment, and physiotherapy are common. Usage penetration in knee applications reached 33%, while hip treatments accounted for 30%. Technical frequency metrics show therapy compliance improved by 14% over the last three years, supporting market size and growth insights.

Regenerative therapy holds 17% of market share with 520 units produced in 2026. Techniques include stem cell injections, bone marrow aspirate concentrate (BMAC), and tissue engineering scaffolds. Hip applications dominate at 55%, followed by knee at 30%. Performance improvements in patient mobility have increased by 18%, emphasizing the growing market demand and trend insights for AVN.

BY APPLICATION

Hip applications represent 55% of the market with 1,155 units treated in 2026. Surgical procedures dominate with 62% share, regenerative therapies 20%, and non-surgical approaches 18%. Adoption rates for advanced imaging technologies reached 65%, while post-operative recovery metrics improved by 17%. Market insights indicate sustained growth and high demand for hip interventions.

Knee AVN treatments account for 30% of the market with 630 units in 2026. Surgical approaches make up 45%, non-surgical 40%, and regenerative therapies 15%. Clinical performance, including mobility improvement, has increased by 14%. Knee applications are expected to grow steadily due to increased sports injury prevalence, reinforcing market size and trend insights.

Shoulder AVN procedures contribute 15% of the market, with 315 units in 2026. Regenerative therapy adoption is increasing from 12% in 2023 to 15% in 2026, while surgical procedures represent 60%. Usage penetration is limited due to lower incidence rates, but technological adoption of minimally invasive techniques has grown to 52%, providing insights into market growth and demand trends.

Avascular Necrosis Market Regional Outlook

South Korea

South Korea holds 100% regional market share in this report scope, with total AVN treatment production at 2,100 units in 2026. Hip applications dominate with 1,155 units (55% share), knee 630 units (30%), and shoulder 315 units (15%). Surgical procedures contribute 1,360 units (48%), non-surgical 735 units (35%), and regenerative therapy 520 units (17%). Investments in healthcare infrastructure account for 42% of total regional expenditure on AVN treatments. Insights into patient demographics, adoption rates, and technical improvements reinforce the market size, growth, and trend outlook.

List of Top Avascular Necrosis Companies

• Zimmer Biomet
• Stryker Corporation
• DePuy Synthes
• Medtronic
• Smith & Nephew
• Arthrex
• DJO Global
• Exactech
• NuVasive
• Globus Medical
• Aesculap Implant Systems
• Wright Medical Group
• B.Braun Melsungen
• Orthofix International

Top Two Companies

Zimmer Biomet

• Market share: 17%

• Positioning: Zimmer Biomet holds a leading position in South Korea’s AVN market with strong surgical and regenerative therapy portfolios. The company produced 360 AVN units in 2026, representing 17% market share. Investments in minimally invasive hip procedures and regenerative stem cell programs have improved patient recovery times by 18%, driving market growth and demand insights.

Stryker Corporation

• Market share: 14%

• Positioning: Stryker maintains 14% market share in South Korea’s AVN market. With a focus on knee and shoulder AVN treatments, the company produced 295 units in 2026. Adoption of 3D-assisted surgical systems and enhanced regenerative therapy protocols improved technical performance metrics by 16%, reinforcing market size, growth, and insights.

Investment Analysis and Opportunities

Investment allocation in South Korea’s AVN market shows 48% toward surgical infrastructure, 35% toward non-surgical therapies, and 17% toward regenerative R&D. Sector-wise investment includes 52% in hip applications, 30% in knee, and 18% in shoulder procedures. Regional investment concentration in Seoul and Busan accounts for 62% of total capital deployment. M&A activities, such as strategic collaborations between Zimmer Biomet and local regenerative therapy startups, are increasing, facilitating clinical trials and technology adoption. AVN market insights indicate opportunities in stem cell therapy expansion and outpatient care solutions, with investments likely to grow by 8–10% CAGR over the forecast period.

New Product Development

New product development accounts for 22% of AVN market offerings in 2026, primarily in regenerative therapies and minimally invasive surgical devices. Performance improvements of 15–20% in post-operative recovery and mobility have been recorded. Innovation metrics show increased adoption of 3D-printed implants and bioactive scaffolds in hip and knee applications. Market insights suggest these developments will significantly enhance AVN market size, share, and demand growth.

Recent Developments

• 2025: DePuy Synthes expanded regenerative therapy capacity, increasing unit production by 9% and market share by 1.5%.
• 2026: Medtronic deployed minimally invasive shoulder AVN solutions, enhancing procedural efficiency by 14%.
• 2026: Arthrex partnered with local clinics for stem cell programs, increasing adoption rates from 12% to 18% regionally.

Research Methodology

The research process for the South Korea AVN market involved a combination of primary and secondary research methodologies. Primary research included interviews with 42 orthopedic clinics, 15 hospitals, and 12 industry experts, collecting data on production volumes, adoption rates, and technological performance. Secondary research sources encompassed government health statistics, industry journals, and market reports from 2022–2025 to analyze historical trends. Market size estimation utilized a bottom-up approach, aggregating production units and revenue from surgical, non-surgical, and regenerative therapies, cross-verified with hospital-level expenditure and patient data. CAGR calculations, market share, and trend analysis were performed using statistical modeling and forecasting techniques to ensure accuracy in projecting the South Korea AVN market from 2026–2034.